Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…
Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma.
Lok A et al. Haematologica. 2014 Feb 14. [Epub ahead of print]
Long-term outcome of monoclonal (type 1) cryoglobulinemia.
Néel A et al. Am J Hematol. 2014 Feb;89(2):156-61. doi: 10.1002/ajh.23608.
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole A et al. Leuk Lymphoma. 2014 Feb 25. [Epub ahead of print].
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Palumbo A et al. J Clin Oncol. 2014 Jan 13. [Epub ahead of print]. Initial treatment of transplant-eligible patients in multiple myeloma. Rosiñol L et al. Expert Rev Hematol. 2014 Jan…
Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Corradini P et al. Methods Mol Biol. 2014;1109:209-37. doi: 10.1007/978-1-4614-9437-9_12. Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist. Nakamoto Y. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):10-1. doi: 10.1016/j.clml.2013.12.005. Epub 2013 Dec 21. Prognostic value of…
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.Berenson JR et al. Leukemia. 2014 Jan 16. doi: 10.1038/leu.2014.27. [Epub ahead of print].Immunotherapy for multiple myeloma.Rosenblatt J et al. Expert Rev Hematol. 2014 Jan 13. [Epub ahead of print].Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin…
Autologous Stem Cell Transplantation for POEMS Syndrome. Nakaseko C.Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):21-3. doi: 10.1016/j.clml.2013.12.009. Epub 2013 Dec 22. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Patel K et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.209. [Epub ahead of print]. Can autologous bone marrow transplantation improve systolic function…
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematological Cancers. Garcia PD et al. Clin Cancer Res. 2014 Jan 28. [Epub ahead of print]. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Nagel D et al. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.565. [Epub ahead of print]. Cyclin D1 Amplification in Multiple…
Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure.Wohlfarth P et al. Crit Care. 2014 Jan 20;18(1):R20. [Epub ahead of print].Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis.Krieter DH et al. Artif Organs. 2014 Jan 7. doi: 10.1111/aor.12248. [Epub ahead of print].Acupuncture for neuropathic pain due…
Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.Management of bone disease in multiple myeloma.Terpos E…